Piramal Pharma (PPLPHARMA) | Stock Overview & Key Data
Piramal Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹187.00
High: ₹195.06
on September 26, 2025
52 Week Range
Low: ₹181.73
High: ₹307.90
on February 14, 2025
on November 6, 2024
All-Time High: ₹307.90 on November 4, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR251.6B
EPS
0.73
P/E Ratio (TTM)
257.16
Forward P/E
42.12
P/B Ratio
3.06
PEG Ratio
-34.46
Div. Yield
0.07%
ROE
1.12%
Beta
0.055
Debt to Equity
59.77
Financial Highlights
Profitability
Gross Margin
64.11%
Operating Margin
-4.68%
Profit Margin
1.07%
Returns and Earnings
Return on Assets (TTM)
0.58%
Return on Equity (TTM)
1.12%
EBITDA
INR16.3B
Net Income (TTM)
INR980.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR69.13
Quarterly Revenue Growth (YoY)
-0.90%
Quarterly Earnings Growth (YoY)
-0.89%
Dividend Information
Last 12-Month Dividend
₹0.14
Current Dividend Yield
0.07%
3-Year Average Dividend Yield
0.07%
3-Year Average Annual Dividend
₹0.08
3-Year Total Dividends
₹0.25
Ex-Dividend Date
July 16, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Piramal Pharma PPLPHARMA | 251.62B Large-cap | -4.00% | 1.23% | -3.34% | -13.90% | -24.41% | -12.51% | 13.82% | 13.82% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | -1.29% | -1.77% | -2.53% | -7.78% | -13.89% | -16.49% | 71.55% | 221.05% |
| Divi's Laboratories DIVISLAB | 1.52T Large-cap | -3.52% | -5.63% | -10.47% | 0.96% | -2.90% | 8.05% | 59.15% | 92.40% |
| Cipla CIPLA | 1.23T Large-cap | -4.34% | -5.71% | 0.18% | -0.10% | 2.05% | 4.88% | 35.41% | 95.30% |
| Torrent TORNTPHARM | 1.22T Large-cap | -1.00% | -3.89% | 9.45% | 8.83% | 3.31% | 1.41% | 126.41% | 25.36% |
| Dr. Reddy's DRREDDY | 1.04T Large-cap | -3.59% | -0.68% | -4.95% | 8.26% | -6.85% | -5.54% | 47.06% | 24.72% |
Ownership & Short Interest
Insider Ownership
54.67%
Institutional Ownership
21.49%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
4M
Average 90-Day Volume
4M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PPLPHARMA's 52-week high and low?
- In the last 52 weeks, Piramal Pharma reached a high of ₹307.90 (on November 6, 2024) and a low of ₹181.73 (on February 14, 2025).
- What is the market cap and P/E ratio for PPLPHARMA?
- Curious about Piramal Pharma's size and valuation? Its market capitalization stands at 251.62B. When it comes to valuation, the P/E ratio (trailing twelve months) is 257.16, and the forward P/E (looking ahead) is 42.12.
- Does PPLPHARMA pay dividends? If so, what's the yield?
- Yes, Piramal Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.07%, and the company has paid an average of ₹0.08 per share annually over the past 3 years.
- Who are Piramal Pharma's main competitors or similar companies to consider before investing?
When looking at Piramal Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -16.49% 71.55% Divi's Laboratories
DIVISLAB1.52T Healthcare Drug Manufacturers - Specialty & Generic 8.05% 59.15% Cipla
CIPLA1.23T Healthcare Drug Manufacturers - Specialty & Generic 4.88% 35.41% Torrent
TORNTPHARM1.22T Healthcare Drug Manufacturers - Specialty & Generic 1.41% 126.41% Dr. Reddy's
DRREDDY1.04T Healthcare Drug Manufacturers - Specialty & Generic -5.54% 47.06% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Piramal Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Piramal Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 1.12%, the Debt to Equity ratio from the most recent quarter is 59.77, and its Gross Profit Margin stands at 64.11%.
- What is the recent revenue and earnings growth for PPLPHARMA?
- Looking at Piramal Pharma's growth, its revenue over the trailing twelve months (TTM) was INR91B. Compared to the same quarter last year (YoY), quarterly revenue grew by -0.90%, and quarterly earnings saw a YoY growth of -0.89%.
- How much of PPLPHARMA stock is held by insiders and institutions?
- Wondering who owns Piramal Pharma stock? Company insiders (like executives and directors) hold about 54.67% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 21.49%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.